Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflect continued ...
Teva Pharmaceutical Industries (NYSE:TEVA) reported first-quarter 2026 results that management said reflected continued ...
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eric Hughes, Teva's EVP of Global R&D & Chief Medical Officer, will present at the BofA Securities Health Care Conference ...
In the days when that healthcare segment was relatively limited, Teva ruled its niche. But success attracts competition, and ...
Teva Pharmaceuticals CEO Richard Francis joins 'Money Movers' to discuss the company's latest acquisition of Emalex Biosciences, their latest drug offerings, and more.
April 29 (Reuters) - Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped ...
On April 29, 2026, Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced entering into a definitive agreement to ...
Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced ...
Teva exceeded all sustainability-linked bond targets, linking financial performance to expanded patient access to medicines and reduced environmental impact.Through its global access to medicines prog ...
April 29 () - Teva Pharmaceutical Industries beat Wall Street estimates for first-quarter profit on Wednesday, helped by ...
Teva Pharmaceuticals has struck a deal to buy Emalex Biosciences for $700 million | Teva Pharmaceuticals has struck a deal to ...
Life Sciences' $400 million commitment to Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in March could be an example.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results